|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kudo M: Surveillance, diagnosis,
treatment, and outcome of liver cancer in Japan. Liver Cancer.
4:39–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao YY, Chen H, Zhou YY, Wang LT, Hou Y,
Xia XH and Ding Y: Intraorgan targeting of gold conjugates for
precise liver cancer treatment. ACS Appl Mater Interfaces.
9:31458–31468. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology 127 (5 Suppl 1). S5–S16. 2004.
|
|
6
|
Palmer WC and Patel T: Are common factors
involved in the pathogenesis of primary liver cancers? A
meta-analysis of risk factors for intrahepatic cholangiocarcinoma.
J Hepatol. 57:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vigil D, Kim TY, Plachco A, Garton AJ,
Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL and
Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer
anchorage-independent growth and invasion. Cancer Res.
72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Ke J, Wang Q, Qian H, Yang L, Zhang
X, Xiao J, Ding H, Shan X, Liu Q, et al: Upregulation of ROCK2 in
gastric cancer cell promotes tumor cell proliferation, metastasis
and invasion. Clin Exp Med. 17:519–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2J. Gut. 61:278–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rath N and Olson MF: Rho-associated
kinases in tumorigenesis: Re-considering ROCK inhibition for cancer
therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroiss A, Vincent S, Decaussin-Petrucci M,
Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli
N: Androgen-regulated microRNA-135a decreases prostate cancer cell
migration and invasion through downregulating ROCK1 and ROCK2.
Oncogene. 34:2846–2855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng F, Jiang J, Yu Y, Tian R, Guo X, Li
X, Shen M, Xu M, Zhu F, Shi C, et al: Direct targeting of
SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma
tumourigenesis and metastasis. Br J Cancer. 109:3092–3104. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Colden M, Dar AA, Saini S, Dahiya PV,
Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S:
MicroRNA-466 inhibits tumor growth and bone metastasis in prostate
cancer by direct regulation of osteogenic transcription factor
RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ji J, Shi J, Budhu A, Yu Z, Forgues M,
Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang S and He X: The role of microRNAs in
liver cancer progression. Br J Cancer. 104:235–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lepage C, Capocaccia R, Hackl M, Lemmens
V, Molina E, Pierannunzio D, Sant M, Trama A and Faivre J;
EUROCARE-5 Working Group, : Survival in patients with primary liver
cancer, gallbladder and extrahepatic biliary tract cancer and
pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5. Eur J
Cancer. 51:2169–2178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dourado MR, de Oliveira CE,
Sawazaki-Calone I, Sundquist E, Coletta RD and Salo T:
Clinicopathologic significance of ROCK2 expression in oral squamous
cell carcinomas. J Oral Pathol Med. 47:121–127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Z, Hong Z, Ma M, Liu X, Chen L, Zheng
C, Xi X and Shao J: Rock2 promotes RCC proliferation by decreasing
SCARA5 expression through β-catenin/TCF4 signaling. Biochem Biophys
Res Commun. 480:586–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
